Posted by Michael Wonder on 14 Dec 2016
Express Scripts announces enhancements to industry leading SafeGuardRx programs
12 December 2016 - Hepatitis cure value program expands covered treatments to include both Viekira Pak and Harvoni in 2017.
As part of its ongoing mission to put medicine within reach, Express Scripts today announced enhancements to its landmark SafeGuardRx programs focusing on hepatitis C and cancer.
Beginning 1 January 2017, the company's Hepatitis Cure Value Program will now include both Viekira Pak/XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir) and Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) as preferred products. With this update, Express Scripts leverages the success of the Hepatitis Cure Value Program to negotiate better pricing for Harvoni and thereby expand treatment options for patients and physicians in 2017, while continuing to lower the cost of treatment by nearly 50%.
Coincident with this change to the Hepatitis Cure Value Program, Express Scripts' National Preferred Formulary, covering more than 25 million Americans, is extending preferred coverage of hepatitis C treatments to include both Viekira Pak/XR and Harvoni.
